EMA 'Completely Reworks' Parts Of Gene Therapy Products Guideline
Executive Summary
The European Medicines Agency has revised several sections of its 2001 guidance on the development and evaluation of gene therapy medicinal products based on stakeholder feedback and to address issues in light of the experience gained with these products.
You may also be interested in...
Familiar Principles In Gene Therapy Guidance For Rare Diseases
Use of historical controls and alternative study designs are allowed, but randomized control trial is preferred.
EMA Close To Finalizing Gene Therapy Products Guidance; No Scope For Further Approximation To International Norms
The European Medicines Agency says there is no scope to harmonize further its guidance on gene therapy medicinal products with international norms as the main focus of the document is on fulfilling data requirements to support an EU marketing authorization application.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.